Concordantly, Wang et al. examined protein expression levels of EZH2 in 67 patients with SCCHN and found significant correlations with tumor stage, lymph node metastasis and clinical stage, while multivariate analysis identified EZH2 as an independent predictor of overall survival [24]. Here, EZH2 is linked to metastatic malignant neoplasm in the lymph nodes.